US drug approvals
120 approvals with a product on the US market
- Afatinib Dimaleate ANDA210804 · approved 21 Oct 2026
- Dasatinib ANDA219579 · approved 11 Sep 2026
- Tapentadol Hydrochloride ANDA220865 · approved 3 Sep 2026
- Pomalidomide ANDA210245 · approved 2 Sep 2026
- Cabozantinib S-Malate ANDA213878 · approved 14 Aug 2026
Source: Drugs@FDA, Approvals (NDA, ANDA, BLA) held, with a product sold now; newest shown. Retrieved 13 Nov 2026.